Examining molecular characteristics of phlegm-heat syndrome in ischemic stroke
Molecular Network Characteristics of Phlegm-heat Syndrome in Ischemic Stroke Based on Multi-omics Integrated Analysis
This study is trying to find out if certain biological markers in the blood can help understand how patients with acute ischemic stroke, who have a specific condition called phlegm-heat syndrome, recover over 90 days.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 24 (estimated) |
| Ages | 50 Years to 80 Years |
| Sex | All |
| Sponsor | Dongzhimen Hospital, Beijing Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT05626296 on ClinicalTrials.gov |
What this trial studies
This observational cohort study focuses on patients with acute ischemic stroke to identify and validate the molecular characteristics and biomarkers associated with phlegm-heat syndrome. Participants will have their demographic data, traditional Chinese medicine (TCM) syndromes, and baseline information recorded, along with blood samples collected for multi-omics analysis. The study aims to follow these patients for 90 days post-onset, assessing their clinical outcomes using the modified Rankin scale (mRS). The goal is to establish a connection between identified biomarkers and clinical outcomes in ischemic stroke patients.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 50 to 80 who have experienced an acute ischemic stroke within the last 72 hours and have been diagnosed with either phlegm-heat syndrome or non-phlegm-heat syndrome.
Not a fit: Patients who are receiving intravenous thrombolysis or endovascular treatment, or those with severe underlying health conditions, will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of ischemic stroke through targeted biomarkers.
How similar studies have performed: While this approach is innovative in its integration of multi-omics analysis with traditional Chinese medicine concepts, similar studies have shown promise in identifying biomarkers for other conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Acute ischemic stroke, were confirmed by magnetic resonance imaging (MRI). * Symptom onset within 72 hours. * Diagnosis of phlegm-heat syndrome or non-phlegm-heat syndrome. * Male or female ≥ 50 years and ≤ 80 years. * With written informed consent. Exclusion Criteria: * Planned or already receiving intravenous thrombolysis or endovascular treatment. * Acute infectious diseases or acute exacerbations of chronic diseases within one month before enrollment. * Patients with previous stroke. * Renal or hepatic insufficiency, tumors, immune diseases, severe underlying diseases. * Other conditions that may affect the collection and evaluation of clinical information (e.g., severe aphasia, mental illness).
Where this trial is running
Beijing, Beijing Municipality
- Dongzhimen Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Xinxing Lai
- Email: new-star@163.com
- Phone: 8615901111280
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.